Trial-to-Paid ConversionHealthTechSeries A

Trial-to-Paid Conversion for HealthTech at Series A

2026 data · Sample size: 593 · Source: Stripe Revenue Growth Benchmarks

25th %ile

6.2%

Median

10.5%

75th %ile

16%

90th %ile

20%

▬Trending stable year-over-year

About This Metric

Percentage of free trial users who convert to paid customers.

Paid Conversions / Trial Signups × 100

Higher is better · Unit: percentage

How to Improve

Ensure trial users reach the activation point within the first few days. Send targeted email sequences based on in‑trial behavior and usage. Offer trial extensions to users who are engaged but not yet converted. Build a clear upgrade path with visible premium features. Implement a reverse trial that starts with full features and downgrades to free.

Ehsan's Analysis

HealthTech trial-to-paid is typically measured as "pilot-to-contract" and the benchmark is 30-50% — lower than SaaS because healthcare pilots involve clinical validation, regulatory review, and multi-stakeholder approval. The pilot-to-contract conversion increases to 70%+ when the pilot includes measurable clinical outcomes. A healthtech company that can show "our AI reduced false positive rates by 23% during the 90-day pilot" converts at dramatically higher rates than one that says "users liked it." Design your pilot with a pre-agreed success metric and measurement methodology. If the pilot hits the metric, the contract should be essentially pre-approved. Healthtech companies that run open-ended pilots ("try it and see") convert at 25%. Those with success-metric-driven pilots convert at 65%+. The pilot design IS the conversion strategy.

Ehsan Jahandarpour

AI Growth Strategist & Fractional CMO

Forbes Top 20 Growth Hacker · TEDx Speaker · 716 Academic Citations · Ex-Microsoft · CMO at FirstWave (ASX:FCT) · Forbes Communications Council

Frequently Asked Questions

What is a good Trial-to-Paid Conversion for HealthTech companies at Series A stage?

The median Trial-to-Paid Conversion for HealthTech companies at the Series A stage is 10.5%. Top‑quartile companies (75th percentile) significantly outperform this baseline. The most important factor is consistent improvement over time rather than hitting any single target number.

How does Trial-to-Paid Conversion differ by company stage in HealthTech?

Trial-to-Paid Conversion typically improves as HealthTech companies mature from seed through growth stage. Earlier‑stage companies should benchmark against stage‑appropriate peers rather than comparing themselves to mature companies.

How often should HealthTech companies measure Trial-to-Paid Conversion?

HealthTech companies at the Series A stage should track Trial-to-Paid Conversion monthly with quarterly deep‑dive analysis. Set up automated dashboards and alerts for significant deviations from your baseline.

What factors most impact Trial-to-Paid Conversion in the HealthTech sector?

In HealthTech, the primary factors impacting Trial-to-Paid Conversion include product‑market fit maturity, competitive landscape intensity, customer segmentation strategy, pricing optimization, and operational efficiency. Series A‑stage companies should focus on the one or two highest‑leverage factors rather than trying to optimize everything simultaneously.

How does Trial-to-Paid Conversion for HealthTech compare to cross‑industry benchmarks?

HealthTech Trial-to-Paid Conversion benchmarks can differ significantly from cross‑industry averages due to factors specific to the HealthTech vertical including customer acquisition dynamics, competitive intensity, and typical deal sizes. Always compare against industry‑specific benchmarks rather than broad averages for meaningful insights.